Business, energy, technology, markets and global industry news from Business News Today
PharmaDeviceNews
Students practise precision pipetting in a biotechnology laboratory, reflecting BioBuilder Educational Foundation’s nearly $1 million Massachusetts grant to develop AI-guided laboratory skills training for high school learners. Representative image.
Pharma & Biotech

BioBuilder secures nearly $1m Massachusetts grant for AI-guided biotech training

BioBuilder’s nearly $1 million Massachusetts grant will test AI coaching for biotech laboratory skills in an initial pilot reaching about 850 students.

Read More
OneLegacy’s partnership with OrganOx aims to expand access to normothermic liver perfusion technology and help Southern California transplant centres evaluate and preserve more donor livers for transplantation. Representative image.
Features & Analysis

Can OneLegacy’s OrganOx perfusion hub turn more donor livers into viable transplants?

OneLegacy is expanding OrganOx metra liver perfusion access across Southern California, testing whether a shared hub can increase transplant capacity.

Read More
A clinician reviews lymphoma treatment data as Genmab and AbbVie clarify that the Phase 3 EPCORE DLBCL-1 trial missed its sole United States overall survival endpoint despite a progression-free survival benefit for epcoritamab. Representative image.
Pharma & Biotech

Genmab and AbbVie clarify EPCORE DLBCL-1 missed sole US overall survival endpoint

Genmab and AbbVie clarify that EPCORE DLBCL-1 missed its sole US overall survival endpoint despite a PFS benefit for epcoritamab.

Read More
MindWalk’s ReefIQ platform aims to connect complex biological data with AI-powered drug discovery workflows running on advanced computing infrastructure. Representative image.
Medical Devices & Diagnostics

MindWalk says AI models are replaceable. Can ReefIQ make biological context the real drug discovery moat?

MindWalk debuts ReefIQ on AMD Instinct, testing whether governed biological context can become the infrastructure moat in AI drug discovery.

Read More
Avacta’s upcoming AVA6103 clinical data will test whether its sustained-release exatecan therapy can concentrate cancer treatment inside tumours while limiting systemic exposure. Representative image.
Features & Analysis

Avacta previews AVA6103 pharmacokinetic data as sustained-release cancer drug faces first human test

Avacta’s next AVA6103 data will test sustained exatecan release in cancer patients. Read what the FOCUS-01 results could mean for its platform.

Read More
Summit Therapeutics enters a pivotal phase for ivonescimab as the oncology developer deploys its $690.7 million cash position toward an upcoming FDA decision, HARMONi-3 data and an expanding late-stage lung cancer programme. Representative image.
Pharma & Biotech

Summit Therapeutics has $690.7m, but one November FDA decision now towers over everything

Summit Therapeutics ends Q2 with $690.7m as ivonescimab approaches an FDA decision and pivotal HARMONi-3 data in late 2026.

Read More
GE HealthCare’s CFO transition and preliminary second-quarter 2026 revenue growth place leadership continuity, earnings momentum and reaffirmed guidance in focus ahead of its full results. Representative image.
Pharma & Biotech

What GE HealthCare’s CFO transition means before its July 29 earnings report

GE HealthCare names George Newcomb interim CFO as preliminary Q2 revenue rises 5.7% and 2026 guidance holds before July 29 results.

Read More
Align Technology’s latest Invisalign digital platform innovations connect AI-assisted diagnostics, 3D treatment planning and patient engagement across modern dental workflows. Representative image.
Medical Devices & Diagnostics

Align Technology expands Invisalign digital platform with AI-assisted diagnostics and 3D treatment planning

Align Technology adds AI-assisted diagnostics, 3D facial simulation and restorative planning tools to its connected Invisalign ecosystem.

Read More
Calocurb clinical trial finds weight and fat reduction without measured muscle loss
Pharma & Biotech

Can a bitter hop supplement protect muscle during weight loss? Calocurb trial offers an early answer

A 24-week Calocurb trial found 4.3% weight loss and reduced fat without measured muscle loss, but important evidence limitations remain.

Read More
Representative image: Corporate and clinical teams review melanoma trial data as Scancell moves to acquire Neuphoria Therapeutics $NEUP and secure up to $89 million to fund the Phase 3 iSCIB1+ immunotherapy program.
Pharma & Biotech

Scancell secures path to $89m financing through Neuphoria Therapeutics merger

Scancell will acquire Neuphoria Therapeutics and pursue up to $89 million to fund the Phase 3 iSCIB1+ melanoma trial through 2028.

Read More